ACOG 2026 Reflects a shift in Women’s Health innovation
Despite representing a substantial global disease burden, women’s health has been chronically underfunded and overlooked by therapeutic innovation. Conditions affecting millions of women globally, including menopause, endometriosis, and postpartum depression (PPD), have often been dismissed as aspects of aging or reproductive life rather than recognized as serious chronic health conditions requiring dedicated care and innovation.
However, discussions emerging from the 2026 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG) reflect a broader shift now underway across the field. While progress remains uneven, menopause has emerged as a clear example of shifting clinical practice, with increasing patient demand for new therapies, and growing pharmaceutical interest in women’s health.
Menopause: From stigma to growth market
Menopause is characterized by prolonged hormonal changes linked to hot flashes, sleep disruption, genitourinary symptoms, and cognitive and metabolic changes. Despite its widespread prevalence and burden, menopause care has historically been fragmented and undertreated. Through the late 20th century, menopausal hormone therapy (MHT) became widely adopted using systemic estrogen therapies with or without progestins. Local estrogen formulations also became used for genitourinary symptoms, offering targeted symptom relief with lower systemic exposure.
The modern menopause landscape was heavily shaped by the 2002 Women’s Health Initiative (WHI) study, which linked combined estrogen-progestin therapy to increased risks of breast cancer, cardiovascular disease, and thromboembolic events. The findings fundamentally altered both physician and public perception of MHT and triggered a dramatic decline in hormone therapy prescribing worldwide.
However, long-term follow-up studies and re-analysis of the WHI data have significantly changed the understanding of MHT risks and benefits. Evidence now suggests outcomes vary based on age, timing of MHT initiation, route of administration, and treatment duration. Current guidance increasingly supports MHT for women within ten years of menopause onset or before age 60, where benefit-risk profiles appear most favorable. In eligible women, MHT remains the gold standard and preferred first-line treatment for menopausal symptoms.
This shift has renewed industry and clinical interest in menopause care, particularly through the development of non-hormonal therapies targeting neurokinin signaling pathways involved in thermoregulation. Astellas Pharma’s Veozah (fezolinetant), the first neurokinin 3 receptor antagonist approved for moderate-to-severe vasomotor symptoms, marked a major clinical and commercial milestone by offering an effective non-hormonal alternative for women unable or unwilling to use hormone therapy. The 2025 FDA approval of Bayer’s Lynkuet (elinzaetant; NK1/3 receptor agonist) further reinforced momentum in the space.
Non-hormonal therapies are also gaining relevance in supportive care for adjacent therapeutic areas, such as oncology. Women with hormone-sensitive breast cancers have historically had limited options for treating menopausal symptoms because of concerns around systemic hormone exposure. The growing visibility of therapies like Lynkuet, including its commercial presence at the European Society of Medical Oncology – Breast Cancer ( ESMO BC 2026), reflects increasing recognition of the substantial unmet need among breast cancer survivors experiencing menopause-related symptoms.
Beyond menopause: Broader changes in women’s health
While menopause is currently one of the most commercially active segments in women’s health, similar shifts are beginning to emerge across several other historically neglected conditions.
Endometriosis affects approximately 10% of reproductive-age women globally and is associated with an average 4–11-year diagnostic delay, with diagnosis relying on surgical findings. Updated guidelines from organizations including ACOG in March 2026 and the UK’s National Institute for Health and Care Excellence (NICE) in 2024 increasingly recognize MRI as an important diagnostic tool for endometriosis, reflecting broader efforts to improve earlier diagnosis and reduce dependence on surgical confirmation alone. Simultaneously, growing investment in non-invasive diagnostics (e.g., Matricis.ai’s EndomAI, Spago Nanomedical’s SpagoPix) signals increased recognition of the substantial unmet need in endometriosis care.
Postpartum depression (PPD) represents another rapidly evolving area. Despite affecting approximately 500,000 women annually in the US, PPD has remained significantly underdiagnosed and undertreated. However, recent commercial momentum surrounding neuroactive steroid therapies is beginning to reshape the landscape. Biogen’s Zurzuvae (zuranolone; GABA-A modulator) has continued to demonstrate strong commercial uptake as OB-GYNs increasingly integrate mental health screening into routine postpartum care. At the same time, next-generation approaches including oral neuroactive steroids (Lipocine’s LPCN 1154A) and psychedelic-inspired neuropsychiatric therapies (Reunion Neuroscience’s luvesilocin) are advancing through development, reflecting growing recognition that maternal health extends beyond reproductive and gynecologic care alone.
Despite growing momentum, substantial challenges remain
Although women’s health appears to be entering a period of renewed momentum, significant structural barriers continue to block progress. Women’s health indications, particularly menopause and endometriosis, have historically faced low reimbursement rates, limited physician education, and reduced investment from large pharmaceutical companies. Growing commercial activity also highlights emerging opportunities for biopharma to address persistent unmet need through innovation of new therapies or strategic partnerships and acquisitions in women’s health. Even as innovation accelerates, long-term commercial success will likely depend on continued public awareness and further normalization of conversations around menopause, reproductive health, and women’s mental health.
Nevertheless, discussions emerging from ACOG 2026 reflect growing recognition that women’s health conditions are not isolated events, but chronic, multidimensional health issues tied to cognition, cardiovascular disease, mental health, metabolic function, and healthy aging. After decades of stagnation, women’s health is beginning to enter a new era of scientific, clinical, and commercial relevance, creating significant opportunities for biopharma companies to expand investment, develop differentiated therapies, and address longstanding gaps in care across women’s health.
